253 related articles for article (PubMed ID: 2224754)
1. Use of sulfonylurea agents in older diabetic patients.
Peters AL; Davidson MB
Clin Geriatr Med; 1990 Nov; 6(4):903-21. PubMed ID: 2224754
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic agents.
Francisco GE
Prim Care; 1990 Sep; 17(3):499-519. PubMed ID: 2236334
[TBL] [Abstract][Full Text] [Related]
3. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
Bell DS
Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
[TBL] [Abstract][Full Text] [Related]
4. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.
Prendergast BD
Clin Pharm; 1984; 3(5):473-85. PubMed ID: 6435940
[TBL] [Abstract][Full Text] [Related]
5. Insulin: either alone or combined with oral hypoglycemic agents.
Firth RG
Prim Care; 1988 Sep; 15(3):665-83. PubMed ID: 3054969
[TBL] [Abstract][Full Text] [Related]
6. Oral hypoglycemic agents in type II diabetes mellitus.
Lubbos H; Miller JL; Rose LI
Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
[TBL] [Abstract][Full Text] [Related]
7. Hypoglycemia in hospitalized patients treated with sulfonylureas.
Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC
Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
[TBL] [Abstract][Full Text] [Related]
8. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus.
Sobieraj DM; Freyer CW
Ann Pharmacother; 2010; 44(7-8):1334-7. PubMed ID: 20516361
[TBL] [Abstract][Full Text] [Related]
9. [Knack of treatment with oral hypoglycemic drugs in the elderly].
Komatsu M; Hashizume K
Nihon Rinsho; 2006 Jan; 64(1):93-8. PubMed ID: 16408454
[TBL] [Abstract][Full Text] [Related]
10. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
Holstein A; Hahn M; Stumvoll M; Kovacs P
Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
Rosenkranz B
Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
[TBL] [Abstract][Full Text] [Related]
12. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
13. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure.
Vallurupalli S
Ann Pharmacother; 2010 Feb; 44(2):387-90. PubMed ID: 20118140
[TBL] [Abstract][Full Text] [Related]
14. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".
Heine RJ
Horm Metab Res; 1996 Sep; 28(9):522-6. PubMed ID: 8911991
[TBL] [Abstract][Full Text] [Related]
15. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients.
Holstein A; Hammer C; Hahn M; Kulamadayil NS; Kovacs P
Expert Opin Drug Saf; 2010 Sep; 9(5):675-81. PubMed ID: 20553106
[TBL] [Abstract][Full Text] [Related]
16. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
[TBL] [Abstract][Full Text] [Related]
17. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
[TBL] [Abstract][Full Text] [Related]
18. [Use of sulfonylurea (SU) in the treatment of diabetes mellitus].
Tasaka Y
Nihon Rinsho; 1999 Mar; 57(3):663-8. PubMed ID: 10199151
[TBL] [Abstract][Full Text] [Related]
19. Self-reported experience of hypoglycemia among adults with type 2 diabetes mellitus (Exhype).
Pettersson B; Rosenqvist U; Deleskog A; Journath G; Wändell P
Diabetes Res Clin Pract; 2011 Apr; 92(1):19-25. PubMed ID: 21195501
[TBL] [Abstract][Full Text] [Related]
20. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
